Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast
cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early …

Opinion Statement Navigating the complex landscape of breast cancer treatment involves
distinct strategies for luminal and triple-negative subtypes. While neoadjuvant chemotherapy …

Background Neoadjuvant immunotherapy (nIO) has emerged as a treatment option for stage
II–III triple-negative breast cancer (TNBC). While randomised clinical trials (RCTs) …

Introduction Immune checkpoint inhibitors have been particularly effective in treating
cancers with robust immune microenvironments and have been successfully incorporated …

Simple Summary Neoadjuvant therapy, used before surgery, is an important part of breast
cancer treatment. Not only can it shrink tumors, but it can also provide valuable information …

Background Triple‐negative breast cancer (TNBC) is an aggressive subtype of breast
cancer associated with shorter survival and a higher likelihood of the cancer returning. In …

Background The management of early breast cancer (BC) has witnessed an uprise in the
use of neoadjuvant therapy and a remarkable reshaping of the systemic therapy …

Проведен анализ исследований, представленных на конференции SABCS 2022 по
лечению рака молочной железы (РМЖ); выделены 16 наиболее интересных и …

Background Neoadjuvant chemotherapy (NACT) is the mainstay of treatment of stages II and
III triple-negative breast cancer (TNBC). This study aims to evaluate if the addition of …

Breast and gynecologic cancers are common across the world and are associated with
substantial societal and economic burden. Pembrolizumab was among the first immune …